Detection of CYP2C19 polymorphisms

• US 20030059774A1
• Filed: 08/30/2001
• Published: 03/27/2003
• Est. Priority Date: 08/30/2000
• Status: Abandoned Application

• Current Assignee: Sequenom-Gemini Limited
• Original Assignee: Sequenom-Gemini Limited
• Inventors: Olaisson, Erik, Risinger, Carl, Lewander, Tommy, Andersson, Maria Kristina
• Application Number:
  US09/943,531
• Publication Number:
  US 20030059774A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The invention provides methods, PCR primers, sequence determination oligonucleotides, isolated polynucleotides, and kits for determining a human'"'"'s capacity to metabolize a substrate of the CYP2C19 enzyme using genetic analysis.

Claims

1. A method for determining a human'"'"'s capacity to metabolize a substrate of a CYP2C19 enzyme, said method comprising the steps of:

a) isolating single stranded nucleic acids from the human, said nucleic acids encoding 5′

flanking regions of CYP2C19 genes present on each homologous chromosome 10 of the human, wherein said region is represented by a sequence as set forth in SEQ ID NO;

1; and

b) detecting at least two polymorphisms within the region, wherein the polymorphisms are nucleotides present at polymorphic sites represented by positions 352 and 1060 of SEQ ID NO;

1.

2. A sequence determination oligonucleotide suitable for detecting a polymorphic site in a 5′

flanking region of a CYP2C19 gene, said oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO;

2;

SEQ ID NO;

3;

SEQ ID NO;

4;

SEQ ID NO;

5;

SEQ ID NO;

6;

SEQ ID NO;

7;

SEQ ID NO;

20;

SEQ ID NO;

21, SEQ ID NO;

22;

SEQ ID NO;

23;

SEQ ID NO;

24;

SEQ ID NO;

25;

SEQ ID NO;

26;

SEQ ID NO;

27;

SEQ ID NO;

28;

SEQ ID NO;

29;

SEQ ID NO;

30;

SEQ ID NO;

31;

SEQ ID NO;

32;

SEQ ID NO;

33, SEQ ID NO;

34;

SEQ ID NO;

35;

SEQ ID NO;

36; and

SEQ ID NO;

37.

3. An oligonucleotide primer pair suitable for amplifying a 5′

flanking region of a CYP2C19 gene, said primer pair having sequences selected from the group consisting of;

SEQ ID NO;

8 and SEQ ID NO;

9;

SEQ ID NO;

10 and SEQ ID NO;

11;

SEQ ID NO;

12 and SEQ ID NO;

13;

SEQ ID NO;

14 and SEQ ID NO;

15;

SEQ ID NO;

16 and SEQ ID NO;

17; and

SEQ ID NO;

18 and SEQ ID NO;

19.

4. An isolated polynucleotide comprising a sequence as set forth in SEQ ID NO:

1.

5. A kit comprising:

a) a first pair of oligonucleotide primers for amplifying the polymorphic region corresponding to position 352 of SEQ ID NO;

1;

b) a second primer pair for amplifying the polymorphic region corresponding to position 1060 of SEQ ID NO;

1;

c) a first sequence determination oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO;

3;

SEQ ID NO;

6;

SEQ ID NO;

22;

SEQ ID NO;

23;

SEQ ID NO;

27;

SEQ ID NO;

30;

SEQ ID NO;

33; and

SEQ ID NO;

36; and

d) a second sequence determination oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO;

4;

SEQ ID NO;

7;

SEQ ID NO;

24;

SEQ ID NO;

25;

SEQ ID NO;

28;

SEQ ID NO;

31;

SEQ ID NO;

34; and

SEQ ID NO;

37.

6. The kit of claim 5, wherein the first primer pair selected from the group consisting of SEQ ID NO:

8 and SEQ ID NO;

9;

SEQ ID NO;

16 and SEQ ID NO;

17; and

SEQ ID NO;

18 and SEQ ID NO;

19; and

the second primer pair is selected from the group consisting of SEQ ID NO;

10 and SEQ ID NO;

11;

SEQ ID NO;

12 and SEQ ID NO;

13; and

SEQ ID NO;

14 and SEQ ID NO;

15.